4:28 PM
 | 
Jul 14, 2014
 |  BC Extra  |  Clinical News

Cobimetinib/Zelboraf combo meets in metastatic melanoma

Roche (SIX:ROG; OTCQX:RHHBY) said once-daily oral cobimetinib ( RG7421) plus the pharma's Zelboraf vemurafenib met the primary endpoint of improving progression-free survival (PFS) vs. Zelboraf alone in the...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >